Session Title: AMD II
Session Date/Time: Friday 12/09/2014 | 08:00-10:00
Paper Time: 08:56
Venue: Boulevard D
First Author: : M.Gillies AUSTRALIA
Co Author(s): : D. Barthelmes
To describe outcomes of eyes with neovascular AMD treated with intravitreal VEGF inhjibitors according to lesion activity
Observational cohort study.
Treatment-naïve eyes with sub-foveal choroidal neovascularization receiving anti-VEGF therapy enrolled in the Fight Retinal Blindness observational study were included. Lesions were graded at each visit as active if there was intraretinal or subretinal fluid attributable to leak from CNV lesion, or fresh hemorrhage. Eyes were divided into 4 groups based the proportion of visits each eye was graded as active during the first 12 months of treatment (Persistent, High, Moderate and Low activity).
655 eyes were included. Similar mean VA changes compared with baseline were observed in all 4 groups at 12 months (+6.8, +8.3, +6.2 and +5.5 letters for the Low, Moderate, High and Persistent groups respectively; p<0.001 for each group). The mean number of injections given increased only modestly in groups with more active lesions (7.6, 7.9, 8.4, 8.3 respectively, P=0.015). Occult and minimally classic lesions were more frequent in the more active groups (P=0.024).
Persistent activity of neovascular lesions during 12 months after starting intravitreal therapy was not associated with worse visual outcomes in this observational study of AMD